The liver is the primary target organ for hematogenous metastasis of colorectal cancer, and colorectal cancer liver metastasis is one of the key and challenging aspects in its treatment. In order to improve the diagnosis and comprehensive treatment of colorectal cancer liver metastasis in China, the guideline development group has summarized advanced experiences and the latest achievements from both domestic and international sources, and has once again revised and updated the Guideline for the diagnosis and comprehensive treatment of colorectal cancer liver metastases (2025 edition) to continuously provide guidance and reference for clinical practice in this field in China.

Objective To provide scientific and normative guidance for capacity building and quality control standards for vision health management service institutions, thereby promoting the standardization and professional development of the industry, enhancing service quality, and improving the effectiveness of myopia prevention and control. Methods A multidisciplinary expert panel organized by Society of Vision Health Management, Chinese Health Association, based on standards such as the ^"Technical Specifications for Vision Health Management Services for Primary and Secondary School Students^" (T/CHAA 008-2019) and combined with field research data, revised and formed this consensus through multiple rounds of meetings and discussions. Results This consensus clarifies the positioning of service institutions, core service capability requirements (covering basic configuration, personnel and equipment, service processes, scope, and competency levels), and quality control points throughout the service process. It establishes an evaluation framework centered on ^"foundational support - service implementation - management effectiveness - outcome output.^" Conclusion This consensus provides systematic guidance for the standardized construction, capacity evaluation, and quality control of vision health management service institutions, which is of great significance for safeguarding the vision health of children and adolescents.

OBJECTIVE To provide guidance on the scientific and standardized application of artificial intelligence （AI） and multimodal fusion techniques in constructing predictive models for adverse drug reactions （ADR） of antineoplastics， thereby enhancing the safety of antineoplastic therapy. METHODS Jointly initiated by the Clinical Pharmacy and Translational Pharmacy Society of the Liaoning Provincial Life Sciences Association and other professional societies， and organized by the Fourth Affiliated Hospital of China Medical University， the writing group conducted a comprehensive search of domestic and international databases using keywords such as “multimodal data” “artificial intelligence” “adverse drug reactions”“antineoplastics” and “models” to collect guidelines， expert consensuses， and relevant guidance literature. Based on this search， and combined with China’s practical experience in applying AI to oncology pharmaceutical care， a consensus framework and preliminary recommendations were drafted. Following evaluation and discussion by an external expert panel， the writing group incorporated the assessment results and formulated recommendations based on those endorsed by 90% or more of the experts. RESULTS &CONCLUSIONS After multiple rounds of review， discussion and revision， this consensus outlines the process for constructing an ADR prediction model of antineoplastics， encompassing “defining research objectives-data preparation-selection of algorithmic frameworks-design of multimodal data fusion strategies-model training and validation-interpretability analysis-clinical deployment-publication of results”. It also formulates 18 recommendations regarding core aspects such as data preparation， algorithm framwork selection， multimodal data fusion strategy design， model validation and interpretability analysis， and clinical deployment. These recommendations are intended for use by physicians in the field of oncology， clinical pharmacists， researchers， and AI technology developers to assist in making optimal clinical treatment decisions.

OBJECTIVE To provide reference for further unifying and standardizing the quality of home-based pharmaceutical services in close-knit regional medical community of Sichuan and Chongqing， and ensuring medication safety of patients. METHODS Under the guidance of the Chongqing Medical Association and the Chongqing Pharmaceutical Administration Quality Control Center， and led by the Bishan Hospital Affiliated to Chongqing Medical University and the Yongchuan Hospital Affiliated to Chongqing Medical University， 14 medical institutions in the Sichuan-Chongqing region jointly participated. Based on existing regulations， guidelines， and expert consensus， questionnaire survey was conducted to investigate the implementation status of home- based pharmaceutical services within the close-knit regional medical community of Sichuan and Chongqing. Subsequently， the Delphi method was employed for expert consultation and the analytic hierarchy process was used to determine indicator weights， ultimately establishing a quality control system for home-based pharmaceutical services in the close-knit regional medical community of Sichuan and Chongqing. RESULTS & CONCLUSIONS This consensus has established a quality control system for home-based pharmaceutical services within the close-knit regional medical community of Sichuan and Chongqing， encompassing three dimensions： service qualification evaluation， necessity evaluation， and service quality evaluation. Among them， service quality evaluation serves as the core component of the quality control system， incorporating 16 secondary indicators， which are further classified into 9 core indicators and 7 general indicators based on their significance. Meanwhile， this consensus proposes a phased quality control strategy. Under the framework of the close-knit regional medical community in Sichuan and Chongqing， this strategy takes execution priority and execution effectiveness as 69 its core. It allows for flexible handling of the rigid requirements concerning service qualifications and necessity， thereby providing a unified and operable quality control toolkit for the close-knit regional medical community in Sichuan and Chongqing.

OBJECTIVE To standardize the implementation methods for therapeutic drug monitoring （TDM） of meropenem and ensure the accuracy of TDM results， thereby facilitating the scientific development of individualized treatment regimens for meropenem. METHODS The expert consensus was launched by the Society of Therapeutic Drug Monitoring Pharmacists of Chinese Pharmacists Association. The compilation team comprised experts in clinical pharmacy， TDM technology， and pharmaceutical administration， and it was developed in accordance with the relevant recommendations from the methodology handbook of WHO and the guidelines for TDM guidelines development. Twelve clinical questions were selected through a three- round Delphi voting process conducted by the committee， followed by a comprehensive review of relevant original articles， systematic reviews， and guidelines through general databases. The GRADE approach was employed to evaluate the quality of evidence so as to formulate the consensus recommendations. The experts’ opinions were organized， revised and finally formed into a consensus. RESULTS Ultimately， the consensus presented 14 recommendations， mainly regarding all aspects of TDM processes including necessity， method， monitor timing， target PK/PD， medication adjustments based on PK/PD， and the quality control of TDM. CONCLUSIONS This consensus provides standardized methods and process suggestions for meropenem TDM in medical institutions in China， and is of great significance for meropenem individualized drug use， improving clinical efficacy， and ensuring drug safety.

Heatstroke, a life-threatening illness, poses a significant risk to human health, particularly in high-temperature and high-humidity environments. Timely and effective on-site management is critical for improving patient survival and prognosis. Rapid recognition, rapid assessment, and rapid cooling are the cornerstones of pre-hospital care. However, the absence of a standardized protocol for pre-hospital management of heatstroke has impeded the efficacy of treatment. This consensus, initiated by the Expert Group on Heatstroke Prevention of the People's Liberation Army, signifies a collaborative endeavor involving emergency medical personnel, nurses, and administrators from pre-hospital care, emergency departments, and intensive care units in both military and civilian domains. By systematically reviewing evidence-based medicine and clinical expertise in heatstroke prevention, on-site and in-transit care, as well as early treatment in emergency settings, the group has formulated the Expert consensus on pre-hospital emergency management of heatstroke (2024) after extensive discussions and iterative recommendations, which serve as a scientific and standardized framework for pre-hospital heatstroke emergency care. The consensus underscores the pivotal role of enhancing public awareness regarding heatstroke prevention and augmenting the rates of rapid recognition and rapid cooling for effective on-site heatstroke management. In high-risk industries, regions, or seasons for heatstroke, developing scientifically sound plans and conducting practical training can provide effective safety measures. Emergency personnel should undergo specialized training and assessments in knowledge and skills, ambulances should be equipped with effective cooling devices, and hospitals must maintain comprehensive emergency response capabilities. It is recommended to establish a regional heatstroke treatment network to optimize the allocation of emergency resources and streamline processes, thereby improving treatment outcomes and response times.
Heat Stroke/prevention & control* ; Humans ; Emergency Medical Services ; Consensus

With the aging population and the increasing prevalence of chronic non-communicable diseases,the burden of endocrine and metabolic diseases has become substantial and represents a significant portion of medical insurance management and fund expendi-tures.Since the introduction of the basic medical insurance outpatient special disease protection policy in Chongqing in 2002,23 years have passed.During this period,the evidence base for relevant diseases has gradually expanded,and the concepts of diagnosis and treatment,as well as therapeutic technologies,have undergone considerable updates and transformations.The existing medical insur-ance policy urgently needs to be updated to keep pace with modern medical advancements and to provide patients with more advanced and effective medical security services.Therefore,starting from June 1,2025,the Medical Insurance Bureau of Chongqing Municipal-ity will implement a new medical insurance policy reform.To ensure the smooth implementation and operation of this policy,the Endo-crinology and Diabetes Branches of the Medical Association of Chongqing Municipality have organized experts in endocrine metabo-lism and public health.Under the guidance of the Medical Insurance Bureau,these experts have interpreted the new policies related to the diagnostic criteria and reimbursement scope for outpatient special diseases in the field of endocrine metabolism.By integrating the latest guidelines for endocrine and metabolic diseases with the ac-tual medical practice in Chongqing,and through multiple rounds of expert discussions that combine clinical experience with medical in-surance management insights,a consensus has been reached on key aspects such as the reimbursement directory for outpatient spe-cial diseases,optimization of disease diagnostic pathways,and the implementation of standardized diagnosis and treatment protocols.This consensus aims to promote the establishment of a standardized management system.The goal is to enhance the efficiency of medical insurance fund utilization and the rate of disease management achievement,to standardize diagnostic and treatment practices,to curb unreasonable medical expenditures,and to ensure that medical insurance funds are precisely allocated to improve patients'quality of life.This initiative will help achieve full life cycle management of chronic diseases,support the comprehensive implementation of the"Healthy China 2030"action plan in Chongqing,and provide a regional practice reference for the national medical insurance reform.

OBJECTIVE To explore the whole-process pharmaceutical care model of iodine contrast medium and promote the rational clinical use of iodine contrast medium. METHODS Clinical Professional Committee on Rational Drug Use of China Medical Education Association and Expert Committee on Drug Evaluation and Clinical Research of Guangdong Pharmaceutical Association organized domestic experts to establish a working group on the Consensus on the whole-process pharmaceutical care for iodine contrast medium. The working group conducted literature searches， evidence-based analysis， and discussions on the development process， indications， contraindications， adverse drug reactions， drug interactions， drug use for special population， pharmaceutical care， and other key topics to summarize the content and process of the whole-process pharmaceutical care for iodine contrast medium. This consensus was ultimately formed. RESULTS The consensus on whole-process pharmaceutical care for iodine contrast medium included an evaluation of the patient， renal function， combined drug use， and hydration regimen before examination， the presence of contrast agent extravasation or suspected acute adverse reactions during examination， observation time points and follow-up after examination， and the presentation of specific work in each stage through pharmaceutical care flowchart. The medication monitoring record form was also formed to record the work situation. CONCLUSIONS The consensus has established a whole-process pharmaceutical care system for iodine contrast medium， providing scientific evidence for clinical physicians and nursing staff in the rational use of such special drugs， and also serving as a reference for pharmacists in providing related pharmaceutical care.

OBJECTIVE To provide standardized guidance for the clinical application and management of biosimilars， and promote their widespread and rational use in clinical treatment. METHODS The design， planning， and drafting process as well as the full report of Evidence-based Guideline for the Management of Clinical Application of Biosimilars in China （2024 Edition） followed the WHO Handbook for Guideline Development （2nd edition）， which fully considered the best current evidence from evidence-based medicine， multidisciplinary expert experience， and patient preferences and values. Grading of Recommendations Assessment， Development， and Evaluation （GRADE） approach was adopted to evaluate the quality of evidence and determine the strength of recommendations. RESULTS & CONCLUSIONS Evidence-based Guideline for the Management of Clinical Application of Biosimilars in China （2024 Edition） presented 10 recommendations including 7 strong recommendations and 3 weak recommendations. The recommendations covered the entire process of clinical application and management of biosimilars. Medical institutions and relevant health regulatory departments can refer to this guideline for the scientific management of the extrapolation of unapproved indications of biosimilars. Healthcare providers can refer to this guideline for pre-treatment assessments， patient education， pre-treatment regimen before administration， and dosage regimen adjustments. Multidisciplinary medical teams can refer to this guideline to provide pharmacovigilance and patient management throughout the treatment process.

Chronic hepatitis B(CHB)is still a major public health issue in China,and without effective control,it can further progress to liver cirrhosis and liver cancer,bringing huge social and economic burdens.At present,antiviral therapy is the main treatment method for CHB,and integrated traditional Chinese and Western medicine therapy is the characteristic treatment method for CHB in China and can improve clinical efficacy by complementing each other's advantages.In order to promote the concept integrated traditional Chinese and Western medicine collaborative diagnosis and treatment,facilitate the development of integrated traditional Chinese and Western medicine diagnosis and treatment techniques for CHB,and establish standardized disease diagnosis and treatment regimens,Expert Committee on Hepatology in Doctor Society of Integrative Medicine,Chinese Medical Doctor Association,established a consensus expert group to discuss and formulate Expert consensus on integrated traditional Chinese and Western medicine diagnosis and treatment of chronic hepatitis B,which elaborated on the concept of integrated traditional Chinese and Western medicine collaborative diagnosis and treatment from the four aspects of CHB epidemiology,pathogenesis and etiology,integrated traditional Chinese and Western medicine diagnosis and syndrome differentiation,and integrated traditional Chinese and Western medicine therapy and proposed related recommendations,in order to improve the prognosis and quality of life of CHB patients.